US 11,939,397 B2
ENTPD2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
Michael Didonato, San Diego, CA (US); Christoph Erkel, Puchheim (DE); Anna Galkin, Encinitas, CA (US); Scott Glaser, San Diego, CA (US); Klaus Felix Hartlepp, Munich (DE); Yong Jia, San Diego, CA (US); Alexandra Kraus, Munich (DE); Christian Cho-Hua Lee, San Diego, CA (US); Sarah Michelle Rue, San Diego, CA (US); Jian Shi, San Diego, CA (US); and Xenia Karola Wezler, Munich (DE)
Assigned to Novartis AG, Basel (CH)
Appl. No. 17/058,870
Filed by Novartis AG, Basel (CH)
PCT Filed May 29, 2019, PCT No. PCT/IB2019/054422
§ 371(c)(1), (2) Date Nov. 25, 2020,
PCT Pub. No. WO2019/229658, PCT Pub. Date Dec. 5, 2019.
Claims priority of provisional application 62/677,850, filed on May 30, 2018.
Prior Publication US 2021/0155713 A1, May 27, 2021
Int. Cl. C07K 16/40 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/40 (2013.01) [A61K 39/39541 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/55 (2013.01); C07K 2317/92 (2013.01)] 18 Claims
 
1. An antibody or antigen binding fragment thereof that specifically binds to human ENTPD2 protein, wherein the antibody or antigen binding fragment thereof comprises a heavy chain complementary determining region 1 (HCDR1), a heavy chain complementary determining region 2 (HCDR2), a heavy chain complementary determining region 3 (HCDR3), a light chain complementary determining region 1 (LCDR1), a light chain complementary determining region 2 (LCDR2), and a light chain complementary determining region 3 (LCDR3), wherein the antibody or antigen binding fragment thereof is selected from any one of the following:
1) an antibody or antigen binding fragment thereof comprising:
an HCDR1 sequence comprising SEQ ID NO: 1,
an HCDR2 sequence comprising SEQ ID NO: 2,
an HCDR3 sequence comprising SEQ ID NO: 3,
an LCDR1 sequence comprising SEQ ID NO: 14,
an LCDR2 sequence comprising SEQ ID NO: 15, and
an LCDR3 sequence comprising SEQ ID NO: 16;
2) an antibody or antigen binding fragment thereof comprising:
an HCDR1 sequence comprising SEQ ID NO: 4,
an HCDR2 sequence comprising SEQ ID NO: 5,
an HCDR3 sequence comprising SEQ ID NO: 3,
an LCDR1 sequence comprising SEQ ID NO: 17,
an LCDR2 sequence comprising SEQ ID NO: 18, and
an LCDR3 sequence comprising SEQ ID NO: 19; or,
3) an antibody or antigen binding fragment thereof comprising:
an HCDR1 sequence comprising SEQ ID NO: 7,
an HCDR2 sequence comprising SEQ ID NO: 8,
an HCDR3 sequence comprising SEQ ID NO: 9,
an LCDR1 sequence comprising SEQ ID NO: 20,
an LCDR2 sequence comprising SEQ ID NO: 18, and
an LCDR3 sequence comprising SEQ ID NO: 16.